Retargeting adenoviruses for therapeutic applications and vaccines.
Michael A BarryJeffrey D RubinShao-Chia LuPublished in: FEBS letters (2020)
Adenoviruses (Ads) are robust vectors for therapeutic applications and vaccines, but their use can be limited by differences in their in vitro and in vivo pharmacologies. This review emphasizes that there is not just one Ad, but a whole virome of diverse viruses that can be used as therapeutics. It discusses that true vector targeting involves not only retargeting viruses, but importantly also detargeting the viruses from off-target cells.